Hormones, nicotine, and cocaine: Clinical studies

Hormones and Behavior

Volumn 58, Issue 1, 2010, Pages 57-71

  Mello, Nancy K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ACTH; Cigarette smoking; Cocaine; Cortisol; DHEA; Estradiol; HPA axis; Neuroactive hormones; Nicotine; Progesterone

Indexed keywords

ADRENALIN; COCAINE; CORTICOTROPIN; HORMONE; HYDROCORTISONE; LUTEINIZING HORMONE; NICOTINE; PRASTERONE; DOPAMINE UPTAKE INHIBITOR; NICOTINIC AGENT;

ARTICLE; BEHAVIOR; CIGARETTE SMOKING; COCAINE DEPENDENCE; DRUG ABUSE; HEART RATE; HORMONE DETERMINATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MENSTRUAL CYCLE; NONHUMAN; PRIORITY JOURNAL; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANIMAL; METABOLISM;

ANIMALS; COCAINE; DOPAMINE UPTAKE INHIBITORS; HORMONES; HUMANS; NICOTINE; NICOTINIC AGONISTS;

EID: 77953478866     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2009.10.003     Document Type: Article

References (164)

1. al'Absi M., Hatsukami D.K., Davis G.L., Wittmers L.E. Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend. 2004, 73:267-278.
2. al'Absi M., Wittmers L.E., Erickson J., Hatsukami D.K., Crouse B. Attenuated adrenocortical and blood pressure responses to psychological stress in ad libitum and abstinent smokers. Pharmacol. Biochem. Behav. 2003, 74:401-410.
3. Allen S.S., Hatsukami D.K., Christianson D., Nelson D. Withdrawal and pre-menstrual symptomatology during the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smoking abstinence. Nicotine Tob. Res. 1999, 1:129-142.
4. Anker J.J., Larson E.B., Gliddon L.A., Carroll M.E. Effects of progesterone on the reinstatement of cocaine-seeking behavior in female rats. Exp. Clin. Psychopharmacol. 2007, 15:472-480.
5. Diagnostic and Statistical Manual of Mental Disorders 1994, APA, American Psychiatric Association, Washington, DC. Fourth Edition.
6. Balster R.L., Schuster C.R. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J. Exp. Anal. Behav. 1973, 20:119-129.
7. Baron J.A., Comi R.J., Cryns V., Brinck-Johnsen T., Mercer N.G. The effect of cigarette smoking on adrenal cortical hormones. J. Pharmacol. Exp. Ther. 1995, 272:151-155.
8. Becker J.B., Molenda H., Hummer D.L. Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann. N.Y. Acad. Sci. 2001, 937:172-187.
9. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 1996, 36:597-613.
10. Benowitz N.L. Compensatory smoking of low-yield cigarettes. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph No 13. U.S. Department of Health and Human Services, National Insitutes of Health, National Cancer Institute, NIH Pub. No. 02-5074, October 2001, Bethesda, MD 2001, 39-63.
11. Benowitz N.L., Hukkanen J., Jacob P.I. Nicotine chemistry, metabolism, kinetics and biomarkers. Nicotine Psychopharmacology, Handbook of Experimental Pharmacology 2009, 192:29-60. Springer-Verlag, Heidelberg. J.E. Henningfield, E.D. London, S. Pogun (Eds.).
12. Benowitz N.L., Porchet H., Jacob P. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. Nicotine Psychopharmacology: Molecular, Cellular and Behavioural Aspects 1990, 112-157. Oxford University Press, Oxford. S. Wonnacott, M.A.H. Russell, I.P. Stolerman (Eds.).
13. Breslau N., Kilbey M.M., Andreski P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch. Gen. Psychiatry 1993, 50:31-35.
14. Butschky M.F., Bailey D., Henningfield J.E., Pickworth W.B. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol. Biochem. Behav. 1995, 50:91-96.
15. 3H] dopamine release is estrogen and progesterone dependent. Cell. Mol. Neurobiol. 2002, 22:445-454.
16. Caine S.B., Bowen C.A., Yu G., Zuzga D., Negus S.S., Mello N.K. Effect of gonadectomy and gonadal hormone replacement on cocaine self-administration in female and male rats. Neuropsychopharmacology 2004, 29:929-942.
17. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., Cosgrove K.P. Sex and estrogen influence drug abuse. Trends Pharmacol. Sci. 2004, 25:273-279.
18. Castner S.A., Xiao L., Becker J.B. Sex differnces in striatal dopamine: in vivo microdialysis and behavioral studies. Brain Res. 1993, 610:127-134.
19. Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999. Morb. Mortal. Wkly Rep. 2002, 51:300-303. CDC.
20. CDC, 2004. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
21. Annual smoking-attributable mortality, years of potential life lost and productivity losses-United States, 1997-2001. Centers for Disease Control and Prevention. MMWR Morb. Mortal. Wkly Rep. 2005, 54:625-628. CDC.
22. 1 selective antagonist ecopipam (SCH 39166). Behav. Pharmacol. 2003, 14:111-120.
23. Coiro V., Vescovi P.P. Effect of cigarette smoking on ACTH/cortisol secretion in alcoholics after short- and medium-term abstinence. Alcohol Clin. Exp. Res. 1999, 23:1515-1518.
24. Connolly G.N., Alpert H.R. Trends in the use of cigarettes and other tobacco produces: 2000-2007. JAMA 2008, 299:2630-2692.
25. Corrigall W.A. Nicotine self-administration in animals as a dependence model. Nicotine Tob. Res. 1999, 1:11-20.
26. Corrigall W.A., Franklin K.B.I., Coen K.M., Clarke P.B.S. The mesolimbic dopamine system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992, 107:285-289.
27. Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med. 1976, 295:573-577.
28. Curtis L., Buisson B., Bertrand S., Bertrand D. Potentiation of human alpha4beta2 neuronal nicotinic acetylcholine receptor by estradiol. Mol. Pharmacol. 2002, 61:127-135.
29. del Arbol J.L., Munoz J.R., Ojeda L., Cascales A.L., Irles J.R., Mianda M.T., Ruiz Requena M.E., Aguirre J.C. Plasma concentrations of beta-endophin in smokers who consume different numbers of cigarettes per day. Pharmacol. Biochem. Behav. 2000, 67:25-28.
30. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393:295-314.
31. Donny E.C., Caggiula A.R., Mielke M.M., Booth S., Gharib M.A., Hoffman A., Maldovan V., Shupenko C., McCallum S.E. Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 1999, 147:135-142.
32. Donny E.C., Caggiula A.R., Rowell P.P., Gharib M.A., Maldovan V., Booth S., Mielke M.M., Hoffman A., McCallum S. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology (Berl) 2000, 15:392-405.
33. Doron R., Fridman L., Gispan-Herman I., Maayan R., Weizman A., Yadid G. DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 2006, 31:2231-2236.
34. Dudish S.A., Pentel P.A., Hatsukami D.K. Smoked cocaine self-administration in females. Psychopharmacology 1996, 123:79-87.
35. Eser D., Schule C., Romeo E., Baghai T.C., di Michele F., Pasini A., Zwanzger P., Padberg F., Rupprecht R. Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders. Psychopharmacology (Berl) 2006, 186:373-387.
36. Evans S.M. The role of estradiol and progesterone in modulating the subjective effects of stimulants in humans. Exp. Clin. Psychopharmacol. 2007, 15:418-426.
37. Evans S.M., Cone E.J., Henningfield J.R. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J. Pharmacol. Exp. Ther. 1996, 279:1345-1356.
38. Evans S.M., Foltin R.W. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology 2006, 31:659-674.
39. Evans S.M., Haney M., Fischman M.W., Foltin R.W. Limited sex differences in response to "binge" smoked cocaine use in humans. Neuropsychopharmacology 1999, 21:445-454.
40. Evans S.M., Haney M., Foltin R.W. The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology 2002, 159:397-406.
41. Fant R.V., Schuh K.J., Stitzer M.L. Response to smoking as a function of prior smoking amounts. Psychopharmacology 1995, 119:385-390.
42. Feltenstein M.W., See R.W. Plasma progesterone levels and cocaine-seeking in freely cycling female rats across the estrous cycle. Drug Alcohol Depend. 2007, 89:183-189.
43. Field A.E., Colditz G.A., Willett W.C., Longcope C., McKinlay J.B. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J. Clin. Endocrinol. Metab. 1994, 79:1310-1316.
44. Fischman M.W., Schuster C.R. Cocaine self-administration in humans. Fed. Proc. 1982, 41:241-246.
45. Fischman M.W., Schuster C.R., Javaid J., Hatono Y., Davis J. Acute tolerance development to the cardiovascular and subjective effects of cocaine. J. Pharmacol. Exp. Ther. 1985, 235:677-682.
46. Foltin R.W., Fischman M.W. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J. Pharmacol. Exp. Ther. 1991, 257:247-261.
47. Foltin R.W., Fischman M.W. Effects of "binge" use of intravenous cocaine in methadone-maintained individuals. Addiction 1998, 93:825-836.
48. Fu Y., Matta S.G., Gao W., Brower V.G., Sharp B.M. Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-d-aspartate receptors in the ventral tegmental area. J. Pharmacol. Exp. Ther. 2000, 294:458-465.
49. Gasior M., Carter R.B., Wilkin J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 1999, 20:107-112.
50. Gerasimov M.R., Franceschi M., Volkow N.D., Rice O., Schiffer W.K., Dewey S.L. Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 2000, 38:432-437.
51. Gianoulakis C., Dai X., Thavundayil J., Brown T. Levels and circadian rhythmicity of plasma ACTH, cortisol, and beta-endorphin as a function of family history of alcoholism. Psychopharmacology (Berl) 2005, 181:437-444.
52. Glassman A.H., Helzer J.E., Covey L.S., Cottler L.B., Stetner F., Tipp J.E., Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990, 264:1546-1549.
53. Goeders N.E. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 1997, 22:237-259.
54. Goeders N.E. Stress and cocaine addiction. J. Pharmacol. Exp. Ther. 2002, 301:785-789.
55. Goeders N.E. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 2002, 27:13-33.
56. Goeders N.E., Guerin G.F. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 2000, 23:577-586.
57. Goldberg S.R., Spealman R.D., Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 1981, 214:573-575.
58. Gossain V.V., Sherma N.K., Srivastava L., Michelakis A.M., Rovner D.R. Hormonal effects of smoking: II. Effects on plasma cortisol, growth hormone, and prolactin. Am. J. Med. Sci. 1986, 291:325-327.
59. Gourlay S.G., Benowitz N.L. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin. Pharmacol. Ther. 1997, 62:453-463.
60. Gross J., Lee J., Stitzer M.L. Nicotine-containing versus de-nicotinized cigarettes: effects on craving and withdrawal. Pharmacol. Biochem. Behav. 1997, 57:159-165.
61. Harvey D.M., Yasar S., Heishman S.J., Panlilio L.V., Henningfield J.E., Goldberg S.R. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 2004, 175:134-142.
62. Hatsukami D.K., Pickens R.W., Svikis D.S., Hughes J.R. Smoking topography and nicotine blood levels. Addict. Behav. 1988, 13:91-95.
63. Heesch C.M., Negus B.H., Bost J.E., Keffer J.H., Snyder R.W., Eichhorn E.J. Effects of cocaine on anterior pituitary and gonadal hormones. J. Pharmacol. Exp. Ther. 1996, 278:1195-1200.
64. Henningfield J.E., Fant R.V., Buchhalter A.R., Stitzer M.L. Pharmacotherapy for nicotine dependence. CA Cancer J. Clin. 2005, 55:281-299. quiz 322-283, 325.
65. Henningfield J.E., Goldberg S.R. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 1983, 19:1021-1026.
66. Henningfield J.E., Goldberg S.R. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol. Biochem. Behav. 1983, 19:989-992.
67. Henningfield J.E., Schuh L.M., Jarvik M.E. Pathophysiology of tobacco dependence. Psychopharmacology the Fourth Generation of Progress 1995, 1715-1729. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
68. Isaac P.F., Rand M.U. Cigarette smoking and plasma levels of nicotine. Nature 1972, 236:308-310.
69. Jackson L.R., Robinson T.E., Becker J.B. Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. Neuropsychopharmacology 2006, 31:129-138.
70. Jaffe J.H., Martin W.R. Opioid analgesics and antagonists. The Pharmacological Basis of Therapeutics 1990, 485-521. Pergamon Press, New York. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
71. James J.R., Villanueva H.F., Johnson J.H., Arezo S., Rosecrans J.A. Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors. Psychopharmacology (Berl) 1994, 114:456-462.
72. Jones H.E., Garrett B.E., Griffiths R.R. Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J. Pharmacol. Exp. Ther. 1999, 288:188-197.
73. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Nerosci. 1991, 14:299-302.
74. La Ferla J., Anderson D.L., Schalch D.S. Psychoendocrine response to sexual arousal in human males. Psychosom. Med. 1978, 40:166-172.
75. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Nicotine Psychopharmacology, Handbook of Experimental Pharmacology 2009, 192:335-367. Springer-Verlag, Heidelberg. J.E. Henningfield, E.D. London, S. Pogun (Eds.).
76. Lynch W.J., Roth M.E., Carroll M.E. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology 2002, 164:121-137.
77. Maayan R., Lotan S., Doron R., Shabat-Simon M., Gispan-Herman I., Weizman A., Yadid G. Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats. Eur. Neuropsychopharmacol. 2006, 16:329-339.
78. Marinelli M., Piazza P.V. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur. J. Neurosci. 2002, 16:387-394.
79. Marks J.L., Hair C.S., Klock S.C., Ginsburg B.E., Pomerleau C.S. Effects of menstrual phase on intake of nicotine, caffeine, and alcohol and nonprescribed drugs in women with late luteal phase dysphoric disorder. J. Subst. Abuse 1994, 6:235-243.
80. Marx C.E., Trost W.T., Shampine L., Behm F.M., Giordano L.A., Massing M.W., Rose J.E. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology 2006, 186:463-472.
81. Matta S.G., Foster C.A., Sharp B.M. Selective administration of nicotine into catecholaminergic regions of rat brainstem stimulates adrencorticotropin secretion. Endocrinology 1993, 133:2935-2942.
82. Matta S.G., Yitong F., Valentine J.D., Sharp B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998, 23:103-113.
83. McCann D.J. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin. Pharmacol. Ther. 2008, 83:627-630.
84. Mello N.K., Lukas S.E., Mendelson J.H. Buprenorphine effects on cigarette smoking. Psychopharmacology 1985, 86:417-424.
85. Mello N.K., Mendelson J.H. Cocaine, hormones and behavior: clinical and preclinical studies. Hormones, Brain and Behavior 2002, 665-745. Academic Press, New York. D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Fahrbach, R.T. Rubin (Eds.).
86. Mello N.K., Mendelson J.H. Cocaine, hormones and behavior: clinical and preclinical studies. Hormones, Brain and Behavior 2009, 3081-3139. Academic Press, San Diego, CA. 2nd edition. D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Fahrbach, R.T. Rubin (Eds.).
87. Mello, N.K., Mendelson, J.H., in press. Cocaine, hormones and behavior: clinical Studies. In: Rubin, R.T., Pfaff, D.W. (Eds.), Hormone/Behavior Relations of Clinical Importance.
88. Mello N.K., Mendelson J.H., Kelly M. Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. Pharmacol. Biochem. Behav. 2000, 66:275-284.
89. Mello, N.K., Mendelson, J.H., Knudson, I.M., Fivel, P., Kelly, M., Newman, J.L., 2009. Acute effects of progesterone and testosterone on cocaine self-administration by female nonhuman primates. Presented at the 2007 meeting of the College on Problems of Drug Dependence.
90. Mello N.K., Mendelson J.H., Sellers M.L., Kuehnle J.C. Effects of heroin self-administration on cigarette smoking. Psychopharmacology 1980, 67:45-52.
91. Mello N.K., Negus S.S., Knudson I.M., Kelly M., Mendelson J.H. Effects of estradiol on cocaine self-administration and cocaine discrimination by female rhesus monkeys. Neuropsychopharmacology 2008, 33:783-795.
92. Mendelson J.H., Goletiani N.V., Sholar M.B., Siegel A.J., Mello N.K. Effects of smoking successive low- and high-nicotine cigarettes on hypothalamic-pituitary-adrenal axis hormones and mood in men. Neuropsychopharmacology 2008, 33:749-760.
93. Mendelson J.H., Mello N.K., Lukas S.E., Woods B.T., Teoh S.K. Promising new biological and behavioral correlates of the reinforcing properties of drugs. Testing for Abuse Liability of Drugs in Humans. In: Office, U.G.P. (Ed.) 1989, 307-340. NIDA Research Monograph, Rockville, MD. M.W. Fischman, N.E. Mello (Eds.).
94. Mendelson J.H., Mello N.K., Sholar M.B., Siegel A.J., Mutschler N., Halpern J. Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 2002, 27:71-82.
95. Mendelson J.H., Mello N.K., Teoh S.K., Lukas S.E., Phipps W., Ellingboe J., Palmieri S.L., Schiff I. Human studies on the biological basis of reinforcement: a neuroendocrine perspective. Addictive States 1992, 131-155. Raven Press, Ltd., New York. C.P. O'Brien, J.H. Jaffe (Eds.).
96. Mendelson J.H., Sholar M., Siegel A.J., Mello N.K. Effects of cocaine on luteinizing hormone in women during the follicular and luteal phases of the menstrual cycle and in men. J. Pharmacol. Exp. Ther. 2001, 296:972-979.
97. Mendelson J.H., Sholar M.B., Goletiani N.V., Siegel A.J., Mello N.K. Effects of low and high nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005, 30:1751-1763.
98. Mendelson J.H., Sholar M.B., Mutschler N.H., Jaszyna-Gasior M., Goletiani N.V., Siegel A.J., Mello N.K. Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone and prolactin in men. J. Pharmacol. Exp. Ther. 2003, 307:339-348.
99. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 1994, 78:1360-1367.
100. Mutschler N.H., Stephen B.J., Teoh S.K., Mendelson J.H., Mello N.K. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine Tob. Res. 2002, 4:223-228.
101. Nair K.S., Rizza R.A., O'Brien P., Khatariya K., Short K.R., Nehra A., Vittone J.L., Klee G.G., Basu A., Basu R., Cobelli C., Toffolo G., Dalla Man C., Tindall D.J., Melton L.J., Smith G.E., Khosla S., Jensen M.D. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med. 2006, 355:1647-1659.
102. Newman J.L., Mello N.K. Neuroactive gonadal steroid hormones and drug addicton in women. Women and Addiction: A Comprehensive Textbook 2009, 35-64. Guilford Press, New York, NY. K.T. Brady, S.E. Backs, S.F. Greenfield (Eds.).
103. Oncken C., Prestwood K., Cooney J.L., Unson C., Fall P., Kulldorff M., Raisz L.G. Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. Nicotine Tob. Res. 2002, 4:451-458.
104. Paradiso K., Zhang J., Steinbach J.H. The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid. J. Neurosci. 2001, 21:6561-6568.
105. Pasqualini C., Olivier V., Gluibert B., Frain O., Leviel V. Rapid stimulation of striatal dopamine synthesis by estradiol. Cell. Mol. Neurobiol. 1996, 16:411-415.
106. Pasqualini C., Olivier V., Guibert B., Frain O., Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem. 1995, 65:1651-1657.
107. Perkins K.A., Donny E., Caggiula A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1999, 1:301-315.
108. Perkins K.A., Epstein L.H., Stiller R.L., Marks B.L., Jacob R.G. Chronic and acute tolerance to the heart rate effects of nicotine. Psychopharmacology 1989, 97:529-534.
109. Perkins K.A., Fonte C., Sanders M., Meeker J., Wilson A. Threshold doses for nicotine discrimination in smokers and non-smokers. Psychopharmacology 2001, 155:163-170.
110. Perkins K.A., Grobe J.E., Epstein L.H., Caggiula A., Stiller R.L., Jacob R.G. Chronic and acute tolerance to subjective effects of nicotine. Pharmacol. Biochem. Behav. 1993, 45:375-381.
111. Perkins K.A., Grobe J.E., Mitchell S.L., Goettler J., Caggiula A., Stiller R.L., Scierka A. Acute tolerance to nicotine in smokers: lack of dissipation within 2 hours. Psychopharmacology 1995, 118:164-170.
112. Perkins K.A., Sexton J.E., Reynolds W.A., Grobe J., Fonte C., Stiller R.L. Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol. Biochem. Behav. 1994, 47:295-299.
113. Perkins K.A., Stiller R.L., Jennings J.R. Acute tolerance to the cardiovascular effects of nicotine. Drug Alcohol Depend. 1991, 29:77-85.
114. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. NeuroReport 2002, 13:1097-1106.
115. Pickworth W.B., Fant R.V. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology 1998, 23:131-141.
116. Pickworth W.B., Fant R.V., Nelson R.A., Rohrer M.S., Henningfield J.E. Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tob. Res. 1999, 1:357-364.
117. Pierce R.C., Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Behav. Rev. 2006, 30:215-238.
118. Pillitteri J.L., Kozlowski L.T., Sweeney C.T., Heatherton T.F. Individual differences in the subjective effects of the first cigarette of the day; a self-report method for studying tolerance. Exp. Clin. Psychopharmacol. 1997, 5:83-90.
119. Pollock J.D., Koustova E., Hoffman A., Shurtleff D., Volkow N.D. Treatments for nicotine addiction should be a top priority. Lancet 2009, 374:513-514. [Electronic publication ahead of print].
120. Pomerleau C.S., Cole P.A., Lumley M.A., Marks J.L., Pomerleau O.F. Effects of menstrual phase on nicotine, alcohol, and caffeine intake in smokers. J. Subst. Abuse 1994, 6:227-234.
121. Pomerleau C.S., Pomerleau O.F. Euphoriant effects of nicotine in smokers. Psychopharmacology 1992, 108:460-465.
122. Pomerleau O.F., Flessland K.A., Pomerleau C.S., Hariharan M. Controlled dosing of nicotine via an intranasal nicotine aerosol delivery device (INADD). Psychopharmacology 1992, 108:519-526.
123. Rasmusson A.M., Wu R., Paliwal P., Anderson G.M., Krishnan-Sarin S. A decrease in the plasma DHEA to cortisol ratio during smoking abstinence may predict relapse: a preliminary study. Psychopharmacology (Berl) 2006, 186(3):473-480.
124. Robinson M.L., Houtsmuller E.J., Moolchan E.T., Pickworth W.B. Placebo cigarettes in smoking research. Exp. Clin. Psychopharmacol. 2000, 8:326-332.
125. Robinson S.E., James J.R., Lapp L.N., Vann R.E., Gross D.F., Philibin S.D., Rosecrans J.A. Evidence of cellular nicotinic receptor desensitization in rats exhibiting nicotine-induced acute tolerance. Psychopharmacology 2006, 184:306-313.
126. Rose J.E. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology 2006, 184:274-285.
127. Rose J.E., Behm F.M., Westman E.C., Coleman R.E. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend. 1999, 56:99-107.
128. Rose J.E., Behm F.M., Westman E.C., Johnson M. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. 2000, 67:71-81.
129. Rosenberg L., Shapiro S., Kaufman D.W., Slone D., Miettinen O.S., Stolley P.D. Cigarette smoking in relation to the risk of myocardial infarction in young women. Modifying influence of age and predisposing factors. Int. J. Epidemiol. 1980, 9:57-63.
130. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003, 28:139-168.
131. Rupprecht R., Holsboer D.F. Neuropsychopharmacological properties of neuroactive steroids. Steroids 1999, 64:83-91.
132. Rupprecht R., Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999, 22:410-416.
133. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., Troxler T., Gentsch C., Kalkman H.O., Chaperon F., Uzunov V., McAllister K.H., Bertaina-Anglade V., LaRochelle C.D., Tuerck D., Floesser A., Kiese B., Schumacher M., Landgraf R., Holsboer F., Kucher K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
134. Russell M.A.H. Subjective and behavioural effects of nicotine in humans: some sources of individual variation. Progress in Brain Research 1985, 289-302. Elsevier Science Publishers. A. Nordberg, K. Fuxe, B. Helmstedt, A. Sundwall (Eds.).
135. Schmidt P.J., Daly R.C., Bloch M., Smith M.J., Danaceau M.A., St Clair L.S., Murphy J.H., Haq N., Rubinow D.R. Dehydroepiandrosterone monotherapy iin midlife-onset major and minor depression. Arch. Gen. Psychiatry 2005, 62:154-162.
136. Selmaoui B., Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci. 2003, 73:3339-3349.
137. Seyler L.E., Fertig J., Pomerleau O., Hunt D., Parker K. The effects of smoking on ACTH and cortisol secretion. Life Sci. 1984, 34:57-65.
138. Seyler L.E., Pomerleau O.F., Fertig J.B., Hunt D., Parker K. Pituitary hormone response to cigarette smoking. Pharmacol. Biochem. Behav. 1986, 24:159-162.
139. Shahan T.A., Bickel W.K., Madden G.J., Badger G.J. Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 1999, 147:210-216.
140. Sharp B.M., Beyer H.S. Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin. J. Pharmacol. Exp. Ther. 1986, 238:486-491.
141. Sharp B.M., Matta S.G. Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: Dose-dependency and desensitization. Endocrinology 1993, 133:11-19.
142. Shoptaw S., Majewska M.D., Wilkins J., Twitchell G., Yang X., Ling W. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Exp. Clin. Psychopharmacol. 2004, 12:126-135.
143. Sofuoglu M., Babb D.A., Hatsukami D.K. Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women. Pharmacol. Biochem. Behav. 2001, 69:299-304.
144. Sofuoglu M., Babb D.A., Hatsukami D.K. Effects of progesterone treatment on smoked cocaine response in women. Pharmacol. Biochem. Behav. 2002, 72:431-435.
145. Sofuoglu M., Dudish-Poulsen S., Nelson D., Pentel P.R., Hatsukami D.K. Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp. Clin. Psychopharmacol. 1999, 7:274-283.
146. Sofuoglu M., Mitchell E., Kosten T.R. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol. Biochem. Behav. 2004, 78:699-705.
147. Sofuoglu M., Poling J., Gonzalez G., Gonsai K., Oliveto A., Kosten T.R. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp. Clin. Psychopharmacol. 2007, 15:453-460.
148. Sofuoglu M., Yoo S., Hill K.P., Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008, 33:715-720.
149. Soria R., Stapleton J.M., Gilson S.F., Sampson-Cone A., Henningfield J.E., London E.D. Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl) 1996, 128:221-226.
150. Spark R.F. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil. Steril. 2002, 77:S19-S25.
151. Spealman R.D., Goldberg S.R. Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys. J. Pharmacol. Exp. Ther. 1982, 223:402-408.
152. Spohr U., Hofmann K., Steck W., Harenberg J., Walter E., Hengen N., Augustin J., Morl H., Koch A., Horsch A., Weber E. Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels. Atherosclerosis 1979, 33:271-283.
153. Sziraki I., Sershen H., Benuck M., Hashim A., Laitha A. Differences in receptor system participation between nicotine- and cocaine-induced dopamine overflow in nucleus accumbens. N.Y. Acad. Sci. 1999, 877:800-802.
154. Thilbin I., Finn A., Ross S.B., Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br. J. Pharmacol. 1999, 126:1301-1306.
155. Valera S., Vallivet M., Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholinic receptor. Prog. Natl. Acad. Sci. U. S. A. 1992, 89:9949-9953.
156. Vocci F.J., Acri J., Elkashef A. Medication development for addictive disorders: the state of the science. Am. J. Psychiatry 2005, 162:1432-1440.
157. Ward A.S., Haney M., Fischman M.W., Foltin R. Binge cocaine self-administration in humans: Intravenous cocaine. Psychopharmacology 1997, 132:375-381.
158. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. 2000, 2:19-37.
159. West R.J., Russell M.A.H. Cardiovascular and subjective effects of smoking before and after 24 h of abstinence from cigarettes. Psychopharmacology 1987, 98:118-121.
160. Wilkins J.N., Carlson H.E., Van Vunakis H., Hill M.A., Gritz E., Jarvik M.E. Nicotine from cigarette smoking increaes circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology (Berl) 1982, 78:305-308.
161. Winternitz W.W., Quillen D. Acute hormonal response to cigarette smoking. J. Clin. Pharmacol. 1977, 17:389-397.
162. Yang H., Zhao W., Hu M., Becker J.B. Interactions among ovarian hormones and time of testing on behavioral sensitization and cocaine self-administration. Behav. Brain Res. 2007, 184:174-184.
163. Yen S.S.C., Jaffe R.B., Barbieri R.L. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management 1999, W.B. Saunders, Philadelphia. 4th edition.
164. Zinder O., Dar D.E. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol. Scand. 1999, 167:181-188.